Cancer cells in combination with standard chemotherapies

The term 'Cancer cells in combination with standard chemotherapies' refers to a therapeutic context or clinical strategy rather than a specific molecular target, receptor, or enzyme. Cancer cells are characterized by biological hallmarks such as sustained proliferative signaling, evasion of growth suppressors, and resistance to programmed cell death (Hanahan & Weinberg, 2011). Standard chemotherapies are cytotoxic agents designed to exploit these characteristics by interfering with DNA replication or mitotic processes, thereby inducing lethal cellular stress (Chabner & Roberts, 2005). In clinical oncology, these agents are frequently used in combination to address intratumoral heterogeneity and reduce the likelihood of emergent drug resistance. Because this entry describes a broad disease state and a multi-drug treatment modality, it does not represent a single, well-defined pharmacological target for drug development.

Other names

Malignant cellsTumor cellsNeoplastic cellsCytotoxic chemotherapy combination

Standard chemotherapies typically act by inducing DNA damage, inhibiting DNA synthesis, or disrupting microtubule dynamics to trigger apoptosis in rapidly dividing malignant cells (Chabner & Roberts, 2005).